Did you know?
ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.
Free Newsletter
Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!
Free Report
For better result, minimum character length is four(4)
Foundation Medicine, a US company that has developed a...
WuXi PharmaTech’s Q2 results showed the company is...
OrbiMed Advisors will raise $300 million for a new...
WuXi PharmaTech, China’s largest CRO, reported that...
Eddingpharm in-licensed greater-China rights to a novel...
WuXi PharmaTech said one of its contract manufacturing...
3SBio acquired China rights for a novel renal failure...
WuXi PharmaTech signed an exclusive license to the Mayo...
Lorem Vascular of Australia will pay up to $531 million...
WuXi PharmaTech announced that its CMO subsidiary,...
ChinaBio® News
Greg Scott Interviewed at BIO-Europe Spring
How to bring your China assets to China in 8 minutes
"Mr. Bio in China."
Mendelspod Interview
Multinational pharma held to a higher standard in China
